Close
A full list of all our current trials, including open and recruiting trials
All
Antidepressants in Parkinson's Disease. |
Primary Antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis. |
Ambroxol to Slow Progression in Parkinson Disease: A phase III multi-centre randomised placebo-controlled trial |
A phase III prospective, interventional, cohort, superiority study to evaluate the benefit of rapid COVID-19 genomic sequencing (the COVID-19 GENOMICS UK project) on infection control in preventing the spread of the virus in United Kingdom NHS settings. |
Developmental Optimisation using Lavage in Preterm Haemorrhage in Infants in the UK: A national randomised controlled trial on the efficacy of neuro-endoscopic lavage |
A randomised, double blind, parallel group, placebo controlled Phase 3 trial of Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease. |
Phase I/II open label, multicentre clinical trial to assess the safety and efficacy of ssAAV-LK03.hAAT.hcoOTC (Gene Therapy) for paediatric patients with ornithine transcarbamylase deficiency. |
Magnetic resonance Enterography (MRE) or ulTRasound In Crohn’s disease Extended Follow-up for predicting disabling disease. |
Integrating Care for young people with epilepsy. |
Mycophenolate in limited cutaneous systemic sclerosis |
MRI for early response prediction to anti-TNF therapy. |
MS-STAT2 : Multiple Sclerosis - Simvastatin Trial 2. |
Nicotinamide in Glaucoma (NAMinG) |
OPtimal TIMing of Anticoagulation after Stroke |
First in Human Phase I/II Clinical Trial of RAFT for Aniridia Related Keratopathy. |
Phase 1 safety study of Recombinant Surfactant Protein D to prevent neonatal Chronic Lung Disease (nCLD) in preterm infants. |
A prospective randomised controlled phase II clinical trial of rivaroxaban versus warfarin in stroke patients with antiphospholipid syndrome, with or without SLE. |
B
|
C
A phase III prospective, interventional, cohort, superiority study to evaluate the benefit of rapid COVID-19 genomic sequencing (the COVID-19 GENOMICS UK project) on infection control in preventing the spread of the virus in United Kingdom NHS settings. |
D
Developmental Optimisation using Lavage in Preterm Haemorrhage in Infants in the UK: A national randomised controlled trial on the efficacy of neuro-endoscopic lavage |
E
A randomised, double blind, parallel group, placebo controlled Phase 3 trial of Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease. |
F
|
G
H
Phase I/II open label, multicentre clinical trial to assess the safety and efficacy of ssAAV-LK03.hAAT.hcoOTC (Gene Therapy) for paediatric patients with ornithine transcarbamylase deficiency. |
I
J
K
|
L
M
Magnetic resonance Enterography (MRE) or ulTRasound In Crohn’s disease Extended Follow-up for predicting disabling disease. |
Integrating Care for young people with epilepsy. |
Mycophenolate in limited cutaneous systemic sclerosis |
MRI for early response prediction to anti-TNF therapy. |
MS-STAT2 : Multiple Sclerosis - Simvastatin Trial 2. |
N
Nicotinamide in Glaucoma (NAMinG) |
O
OPtimal TIMing of Anticoagulation after Stroke |
P
|
Q
R
First in Human Phase I/II Clinical Trial of RAFT for Aniridia Related Keratopathy. |
Phase 1 safety study of Recombinant Surfactant Protein D to prevent neonatal Chronic Lung Disease (nCLD) in preterm infants. |
A prospective randomised controlled phase II clinical trial of rivaroxaban versus warfarin in stroke patients with antiphospholipid syndrome, with or without SLE. |
S
|
T
|
U
V
W
X
Y
Z